Trazodone
Desyrel
Trazodone (Desyrel) is a cognitive & mood research compound. Serotonin antagonist and reuptake inhibitor. The sedation comes from 5-HT2A and H1 antagonism, which is why low doses sedate more reliably than high ones.
Trazodone quick facts
| Reported research dose | 25–100mg at bedtime for sleep |
| Route | Oral |
| Frequency | 1x · Nightly |
| Half-life | ~7 hours |
| Forms | Oral |
| Evidence level | Used for insomnia far more widely than the evidence strictly supports; a strong trial base for depression at full dose |
Widely prescribed off-label for sleep because it isn't habit-forming. Morning grogginess is the common complaint. ⚠️ Priapism is rare but a documented emergency requiring immediate care. Serotonin syndrome risk if stacked with other serotonergics.
How Trazodone works
Serotonin antagonist and reuptake inhibitor. The sedation comes from 5-HT2A and H1 antagonism, which is why low doses sedate more reliably than high ones.
Proposed benefits
Researched for focus, memory, neuroprotection, mood and stress resilience.
Where to get Trazodone
Buy Trazodone at AlgoRx →The evidence for Trazodone
Graded by what exists behind each claim.
✅ Clinically validated
- Approved as an antidepressant with extensive trial data, and used far more widely off-label at low doses for insomnia — where it has randomized support, though less than its prescribing volume implies.
- Priapism is the rare but genuine risk and is on the label; it is a urological emergency and the reason the drug carries a specific warning.
📊 Correlative data
- One of the most-prescribed sleep aids in the US despite insomnia being an off-label use. Long real-world record — next-day grogginess is the common complaint, dependence is not.
🧪 Theoretical / extrapolated
- A serotonin antagonist and reuptake inhibitor — at low doses it primarily blocks 5-HT2A and H1 receptors, which produces sedation, while the reuptake inhibition needed for antidepressant effect requires much higher doses.
- Alpha-1 adrenergic blockade is the mechanism behind both the orthostatic hypotension and the priapism — the same receptor action, two very different consequences.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Trazodone actually does
Trazodone is the clearest example in this Vault of a drug whose dose does not change how much it does — it changes what it does. The reason is that it binds four different targets with affinities separated by more than an order of magnitude, so as the concentration climbs, targets switch on in a fixed order.
The order, from tightest binding to loosest. 5-HT2A receptor antagonism comes first and is the highest affinity interaction the molecule has. Alpha-1 adrenergic antagonism and H1 histamine antagonism follow close behind. Serotonin transporter inhibition — the SERT block that makes it an antidepressant — is the weakest of the four and requires the highest concentration Fagiolini 2023.
That ordering explains the whole clinical picture. At the 25–100 mg doses used for sleep, you get 5-HT2A blockade plus H1 and alpha-1 blockade with little meaningful SERT inhibition: a sedative with essentially no serotonergic antidepressant action. At the 300–600 mg doses licensed for depression, SERT inhibition finally becomes substantial. The low-dose sleep drug and the high-dose antidepressant are pharmacologically different interventions that happen to share a molecule, and that is why the class name SARI — serotonin antagonist and reuptake inhibitor — puts the antagonism first.
Why 5-HT2A blockade specifically produces good sleep rather than just sedation. 5-HT2A activation promotes wakefulness and suppresses slow-wave sleep. Block it and slow-wave sleep is released. This is a different mechanism from a benzodiazepine or a Z-drug, which act at the GABA-A receptor and increase light sleep while suppressing deep sleep. It is the mechanistic reason trazodone is preferred by clinicians who care about sleep architecture rather than about time to sleep onset Pelayo 2023.
The metabolite is a separate drug and it points the other way. CYP3A4 converts trazodone to m-chlorophenylpiperazine (mCPP), which is a 5-HT2C agonist — and 5-HT2C agonism is anxiogenic and alerting. mCPP is cleared by CYP2D6. So a person who is a poor CYP2D6 metabolizer, or who is taking a CYP2D6 inhibitor, accumulates an activating metabolite of a sedating drug. That is the pharmacogenetic explanation for the minority who report trazodone makes them anxious and wakeful, and it is a real mechanism rather than an idiosyncrasy.
Alpha-1 blockade is the source of the two effects that get people into trouble — orthostatic drops in blood pressure, and the prolonged erections discussed below, which arise because alpha-1 tone is what maintains detumescence Shah 2021.
Cell, rodent, human — and where it stops
Step one, receptor pharmacology: settled, and quantified. Binding affinities across 5-HT2A, alpha-1, H1 and SERT are established and are the basis of the dose-dependent behavior above Fagiolini 2023.
Step two, in humans, with polysomnography — and this is unusually good evidence for a compound in this Vault. Zheng 2022 pooled 11 randomized controlled trials covering 466 patients with insomnia disorder, all with objective sleep-laboratory measurement. Trazodone increased total sleep time by 39.88 minutes, reduced sleep latency by 19.30 minutes, and reduced awakenings (standardized mean difference −0.67). Those are objective, instrument-measured numbers from randomized trials, which almost nothing else on this site can claim.
The same analysis reports the cost. Daytime drowsiness had an odds ratio of 2.53 and decreased appetite an odds ratio of 2.81 against comparator Zheng 2022. A drug that adds 40 minutes of sleep and multiplies the odds of next-day drowsiness by two and a half is a trade, and printing both numbers together is the only honest way to present it.
Step three, the next-day question, examined directly. Goncalo 2021 systematically reviewed trazodone's effects on human cognition. This is the right question for a drug taken nightly for years, and it is the one a sleep-latency number cannot answer.
Step four, the appraisal. Pelayo 2023 asks explicitly whether trazodone should be first-line therapy for insomnia. That such an appraisal was needed is itself informative: trazodone is one of the most-prescribed sleep medications in several countries and is not licensed for insomnia in any of them. Its licensed indication is depression, at doses five to twenty times higher than the sleep dose.
The obstacles, named one at a time. (1) 466 patients across 11 trials is a modest evidence base, and the trials are short against a condition treated for years. (2) Almost none of that evidence is in the healthy, non-depressed adults who use it as a sleep aid. (3) The mCPP pharmacogenetics above have never been used to stratify a trial, so the anxious non-responders are averaged into every result. (4) Tolerance to the sedative effect over months has not been well characterized, which is exactly the timescale that matters to a nightly user.
What would have to be true, and how you would know it was not
Three predictions. The first is how you would know whether it is working for the reason people think, and the second is the one that cuts against nightly use.
1. If the 5-HT2A mechanism is doing the work, deep sleep should rise — and only an instrument can tell you. The claim is architectural, not just sedative Zheng 2022. Actigraphy across two weeks off and two weeks on gives total sleep time and awakenings for the price of a wrist device; a home polysomnograph or a validated ring adds a slow-wave estimate. Feeling rested is not the measurement, because a sedative reliably produces the feeling of having slept whether or not the architecture improved.
2. The falsification test is the morning, not the night. Daytime drowsiness carries an odds ratio of 2.53 in the pooled trials Zheng 2022 and next-day cognition is the subject of its own review Goncalo 2021. So measure the morning: a fixed reaction time or working memory task at the same hour, ten days off and ten days on. If sleep improves by 40 minutes and morning performance falls, the drug has moved the problem rather than solved it, and that is a result no amount of subjective sleep quality can overturn.
3. A CMP has one specific job here, and it is sodium. Serotonergic antidepressants are an established cause of hyponatremia through inappropriate ADH secretion, disproportionately in older adults and in anyone on a thiazide. A CMP at baseline and at 4–6 weeks catches it, and the presenting symptoms of a falling sodium — confusion, fatigue, unsteadiness — are exactly what a person would otherwise dismiss as the drug being sedating.
What nobody has tested yet
Four things that are unstudied about the way trazodone is actually used, which is not the way it is licensed.
Nobody has run a long trial at the sleep dose. The pooled evidence is short-term Zheng 2022 and people take 50 mg nightly for years. A 12-month randomized trial at 50 mg with polysomnography and cognitive endpoints does not exist, and it is the study the actual pattern of use demands.
Nobody has genotyped a trazodone cohort for CYP2D6. The mCPP mechanism predicts that poor metabolizers accumulate an activating metabolite and do worse. CYP2D6 genotyping is cheap and routine. Stratifying responders and anxious non-responders by that genotype is an obvious study and has not been done.
Nobody has established a minimum effective dose. The receptor argument implies that the sedative effect saturates once 5-HT2A and H1 are largely occupied, which may happen well below the 50 mg most people take. A dose-ranging study at 12.5, 25 and 50 mg with polysomnography would identify the point of diminishing returns — and since the adverse effects are dose-related and the benefit may not be, that is where the next-day drowsiness could be reduced without losing anything.
Nobody has tested discontinuation properly. Whether stopping produces genuine rebound insomnia or the return of the original problem is a question with a straightforward taper-versus-abrupt design, and the answer determines whether a nightly user is treating insomnia or maintaining a dependence on a drug that was never licensed for the purpose.
Trazodone — its own safety story, not its class's
Trazodone is a prescription medicine with a full label, so the generic caution block above is the wrong instrument. Here is what is specific.
Prolonged erection is the adverse effect this drug is known for, and it is alpha-1 pharmacology. Detumescence depends on alpha-1 adrenergic tone; trazodone antagonizes alpha-1 receptors, and prolonged or painful erection can result. It is uncommon and it is a urological emergency when it occurs, because an erection persisting beyond about four hours causes ischemic damage to the tissue and permanent dysfunction. Shah 2021 exists precisely because the appropriate response is pretreatment counseling — telling the patient what to watch for and when to go to an emergency department — rather than avoiding the drug. That is the correct handling and it depends entirely on the person having been told.
Orthostatic hypotension is the same receptor with a different consequence. Alpha-1 blockade blunts the vasoconstriction that maintains blood pressure on standing. In an older adult getting up at night, that is a fall risk, and it is the reason this drug is not the benign choice it is often assumed to be in that population.
The interaction to know is CYP3A4, and it runs both directions. Trazodone is metabolized by CYP3A4, so strong inhibitors — several antifungals, some antibiotics, grapefruit — raise its concentration and its sedation. Because CYP3A4 also makes mCPP, the interaction is not simply "more drug": it changes the ratio of parent to activating metabolite, and the direction depends on CYP2D6 status too. This is a genuinely complex interaction and it is the reason trazodone is worth discussing with a prescriber rather than adding to a stack.
Serotonin syndrome, at the right strength. Even weak SERT inhibition is additive with other serotonergic agents — SSRIs, SNRIs, tramadol, triptans, MAOIs, high-dose 5-HTP. The risk at 50 mg alone is low; the risk of adding 50 mg to an existing serotonergic regimen without telling anyone is not, and that is the common scenario when a prescription drug is treated as a sleep supplement.
What this page will not do. Recommend a dose, or suggest using trazodone without a prescriber. This is a licensed antidepressant being used off-label at a fraction of its licensed dose Pelayo 2023; that is a legitimate and common clinical decision, and it is a clinical decision.
Sources read for this page
- Zheng Y, et al. Trazodone changed the polysomnographic sleep architecture in insomnia disorder: a systematic review and meta-analysis. Scientific Reports 2022 · PMID 36002579
- Pelayo R, et al. Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal. Journal of Clinical Medicine 2023 · PMID 37109268
- Goncalo AMG, et al. The effects of trazodone on human cognition: a systematic review. European Journal of Clinical Pharmacology 2021 · PMID 34097124
- Fagiolini A, et al. Role of trazodone in treatment of major depressive disorder: an update. Annals of General Psychiatry 2023 · PMID 37660092
- Shah T, et al. Pretreatment screening and counseling on prolonged erections for patients prescribed trazodone. Investigative and Clinical Urology 2021 · PMID 33314808
Trazodone — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- This group acts directly on established CNS receptors — GABA-B (phenibut), serotonergic and histaminergic (trazodone, doxepin), beta-adrenergic (propranolol), dopaminergic (cabergoline, apomorphine). These are pharmacological drugs, not research peptides, and the predicted problems are the known ones for each receptor.
- Phenibut is the one that needs saying plainly: it is physically addictive. GABA-B agonism produces tolerance within days of regular use, and withdrawal is genuinely severe — anxiety, insomnia, tremor, and in heavy users, psychosis and seizures. It is closer to a benzodiazepine than to a nootropic in this respect, and it is sold as though it were the latter.
- Propranolol blunts the physical symptoms of adrenaline. That predicts the useful effect and also the problem — it blunts the training response and masks hypoglycemia.
- Dopamine agonists predict nausea, orthostatic hypotension and, at the doses used in Parkinson's, impulse-control problems. Cabergoline's half-life is very long, so effects persist well past a dose.
What has actually been reported
- Phenibut dependence and withdrawal are well documented in case reports and poison-center data.
- Trazodone: sedation, orthostatic hypotension, and rarely priapism — which is a medical emergency.
- Abrupt propranolol cessation causes rebound tachycardia and hypertension. Do not stop a beta-blocker suddenly.
- Cabergoline at high cumulative doses is associated with cardiac valve changes; at the low doses used for prolactin this has not been shown.
How to reduce the risk
Same mechanism as the prediction.
- For phenibut, the only reliable mitigation is frequency: occasional use does not produce dependence, regular use does. There is no dose that makes daily use safe.
- Taper anything in this group rather than stopping abruptly.
- Take the first dose of anything with orthostatic effects at home, sitting down.
What it does to your bloodwork
A fact about the assay.
- Prolactin if using cabergoline (it is usually why you are). Otherwise blood pressure and heart rate are the monitoring that matters.
Don't run this if
- You already take a sedative, a benzodiazepine, or drink regularly — the CNS depressant effects are additive and this is where respiratory depression comes from.
- You are on an antidepressant and considering trazodone — serotonergic combinations need a prescriber, not a forum.
The honest unknown
- Most of this group is well characterized for its licensed use. What is NOT characterized is the off-label use most people here are making of it, at doses and durations nobody studied.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Trazodone — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Trazodone moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Trazodone in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Trazodone
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
Trazodone — frequently asked questions
What is Trazodone?
Trazodone (Desyrel) is a cognitive & mood research compound. Serotonin antagonist and reuptake inhibitor. The sedation comes from 5-HT2A and H1 antagonism, which is why low doses sedate more reliably than high ones.
Is the full Trazodone protocol on this page?
The reported research dose is on this page, along with how Trazodone works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Trazodone?
Trazodone has an approximate half-life of ~7 hours, which is part of what determines how often it's dosed.
What's the evidence behind Trazodone?
Current evidence level: Used for insomnia far more widely than the evidence strictly supports; a strong trial base for depression at full dose. Trazodone is offered for research purposes only and is not an approved medicine.
What Trazodone is used for
Trazodone appears under 2 goals in the goal router.
Related Cognitive & Mood compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.